Shares of Zydus Lifesciences fell over 2% in early trade on June 18 following news that its Gujarat unit was classified as “Official Action Indicated” (OAI).
The United States Food and Drug Administration (USFDA) issued this classification after inspecting the injectables manufacturing facility at Pharmez Special Economic Zone in Matoda, Gujarat. The inspection took place from March 18 to March 27, 2024.
In response, Zydus Lifesciences has been granted a teleconference meeting with the regulatory agency to discuss the actions taken and those proposed. The company is committed to working closely with the USFDA to resolve the issues at this facility as quickly as possible.
By 10:10 AM, Zydus Lifesciences shares were trading 2.20% lower at ₹1,085.10 on the NSE.
